Synopsis
Synopsis
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 4-deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4c)rifamycin
2. L 105
3. L-105
4. L105
5. Redactiv
6. Xifaxan
1. Rifaxidin
2. Rifacol
3. 80621-81-4
4. Rifamycin L 105
5. Xifaxan
6. Rifamycin L 105sv
7. Fatroximin
8. Rifaximine
9. Normix
10. Rifaximina
11. Xifaxsan
12. L-105
13. Rifamixin
14. Rifaximine [french]
15. Rifaximinum [latin]
16. Rifaximina [spanish]
17. Ritacol
18. Chebi:75246
19. 4-deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4-c)rifamycin Sv
20. L36o5t016n
21. Rifaximin (xifaxan)
22. Nsc-758957
23. Rifaximinum
24. Brn 3584528
25. (2s,16z,18e,20s,21s,22r,23r,24r,25s,26r,27s,28e)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-1,15-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)furo[2'',3'':7',8']naphtho[1',2':4,5]imidazo[1,2-a]pyridin-25-yl Acetate
26. C43h51n3o11
27. Rifaxin
28. Redactiv
29. Ido[1,2-a]benzimidazol-25-yl Acetate
30. (2s,16z,18e,20s,21s,22r,23r,24r,25s,26r,27s,28e)-25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2h)-dione
31. L 105sv
32. L 105 (ansamacrolide Antibiotic)
33. L 105
34. Rifaximinun
35. Flonorm
36. Lumenax
37. Spiraxin
38. Lormyx
39. Rifaximin [usan:inn:ban]
40. Unii-l36o5t016n
41. 5-yl Acetate
42. Ncgc00095842-01
43. (2s,16z,18e,20s,21s,22r,23r,24r,25s,26r,27s,28e)-25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca(1,11,13)trienimino)benzofuro(4,5-e)pyrido(1,2-a)benzimidazole-1,15(2h)-dione
44. (2s,16z,18e,20s,21s,22r,23r,24r,25s,26r,27s,28e)5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-1,15-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)[1]benzofuro[4,5-e]pyr
45. Xifaxan (tn)
46. Mfcd00864973
47. Rifaximin [inn]
48. Rifaximin [jan]
49. Rifaximin [mi]
50. Rifaximin [usan]
51. Rifaximin [vandf]
52. Rifaximin [mart.]
53. Alpha-0817185
54. Rifaximin [who-dd]
55. Chembl1617
56. Dsstox_cid_25998
57. Dsstox_rid_81280
58. Dsstox_gsid_45998
59. (2s,16z,18e,20s,21s,22r,23r,24r,25s,26s,27s,28e)-5,6,21,23,25 Pentahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca(1,11,13)trienimino)benzofuro(4,5-e)pyrido(1,2-a)benzimidazole-1,15(2h)-dione, 25-acetate
60. Rifaximin (jan/usan/inn)
61. Schembl124066
62. Rifaximin [ep Impurity]
63. Rifaximin [orange Book]
64. Dtxsid7045998
65. Rifaximin [ep Monograph]
66. Gtpl12012
67. Hms3715b19
68. 88747-56-2
69. Tox21_111529
70. Bdbm50347620
71. S1790
72. Akos015963053
73. Zinc169621200
74. Ccg-221129
75. Db01220
76. Nsc 758957
77. Rifaximin 100 Microg/ml In Acetonitrile
78. 2,7-(epoxy(1,11,13)pentadecatrienoimino)furo(2'',3'':7',8')naphth(1',2':4,5)imidazo(1,2-a)pyridine-1,15(2h)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, ( 2s,16z,18e,20s,21s,22r,23r,24r,25s,26r,27s,28e)-
79. 2,7-(epoxypentadeca(1,11,13)trienimino)benzofuro(4,5-e)pyrido(1,2-a)benzimidazole-1,15(2h)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, (2s-(2r*,16z,18e,20r*,21r*,22s*,23s*,24s*,25r*,26s*,27r*,28e))-
80. Ac-19112
81. Cas-80621-81-4
82. L/105
83. D02554
84. Ab01209738-01
85. Ab01209738-03
86. Ab01209738_04
87. Rifaximin, Antibiotic For Culture Media Use Only
88. 621r814
89. Q416073
90. Q-201671
91. (2s,16z,18e,20s,21s,22r,23r,24r,25s,26r,27s,28e)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-1,1
92. (7s,11s,12r,13s,14r,15r,16r,17s,18s)-2,15,17,36-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6,23-dioxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.1^{4,7}.0^{5,35}.0^{26,34}.0^{27,32}]heptatriaconta-1,3,5(35),9,19,21,25(36),26(34),28,30,32-undecaen-13-yl Acetate
93. [(7s,9e,11s,12r,13s,14r,15r,16r,17s,18s,19e,21z)-2,15,17,36-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6,23-dioxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.14,7.05,35.026,34.027,32]heptatriaconta-1(35),2,4,9,19,21,25(36),26(34),28,30,32-undecaen-13-yl] Acetate
94. 2,7-(epoxypentadeca(1,11,13)trienimino)benzofuro(4,5-e)pyrido(1,2-a)benzimidazole-1,15(2h)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, (2s,16z,18e,20s,21s,22r,23r,24r,25s,26r,27s,28e)-
95. 5-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)furo[2'',3'':7',8']naphtho[1',2':4,5]imidazo[1,2-a]pyridin-2
| Molecular Weight | 785.9 g/mol |
|---|---|
| Molecular Formula | C43H51N3O11 |
| XLogP3 | 6.9 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 3 |
| Exact Mass | 785.35235945 g/mol |
| Monoisotopic Mass | 785.35235945 g/mol |
| Topological Polar Surface Area | 198 Ų |
| Heavy Atom Count | 57 |
| Formal Charge | 0 |
| Complexity | 1590 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 9 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 3 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Xifaxan |
| PubMed Health | Rifaximin (By mouth) |
| Drug Classes | Antibiotic |
| Drug Label | XIFAXAN tablets contain rifaximin, a non-aminoglycoside semi-synthetic, nonsystemic antibiotic derived from rifamycin SV. Rifaximin is a structural analog of rifampin. The chemical name for rifaximin is (2 ,16 ,18 ,20 ,21 ,22 ,23 ,24 ,25 ,26 ,27... |
| Active Ingredient | Rifaximin |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 200mg; 550mg |
| Market Status | Prescription |
| Company | Salix Pharms |
| 2 of 2 | |
|---|---|
| Drug Name | Xifaxan |
| PubMed Health | Rifaximin (By mouth) |
| Drug Classes | Antibiotic |
| Drug Label | XIFAXAN tablets contain rifaximin, a non-aminoglycoside semi-synthetic, nonsystemic antibiotic derived from rifamycin SV. Rifaximin is a structural analog of rifampin. The chemical name for rifaximin is (2 ,16 ,18 ,20 ,21 ,22 ,23 ,24 ,25 ,26 ,27... |
| Active Ingredient | Rifaximin |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 200mg; 550mg |
| Market Status | Prescription |
| Company | Salix Pharms |
Rifaximin has multiple indications by the FDA: for the treatment of patients (12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients 18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in adult men and women.
FDA Label
Rifaximin is a structural analog of rifampin and a non-systemic, gastrointestinal site-specific antibiotic. This non-systemic property of the drug is due to the addition of a pyridoimidazole ring, which renders it non-absorbable. Rifaximin acts by inhibiting bacterial ribonucleic acid (RNA) synthesis and contributes to restore intestinal microflora imbalance. Other studies have also shown rifaximin to be an pregnane X receptor (PXR) activator. As PXR is responsible for inhibiting the proinflammatory transcription factor NF-kappa B (NF-B) and is inhibited in inflammatory bowel disease (IBD), rifaximin was proven to be effective for the treatment of IBS-D.
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Gastrointestinal Agents
Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)
A07AA11
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
A - Alimentary tract and metabolism
A07 - Antidiarrheals, intestinal antiinflammatory/antiinfective agents
A07A - Intestinal antiinfectives
A07AA - Antibiotics
A07AA11 - Rifaximin
D - Dermatologicals
D06 - Antibiotics and chemotherapeutics for dermatological use
D06A - Antibiotics for topical use
D06AX - Other antibiotics for topical use
D06AX11 - Rifaximin
Absorption
Low absorption in both the fasting state and when administered within 30 minutes of a high-fat breakfast.
Route of Elimination
In a mass balance study, after administration of 400 mg 14C-rifaximin orally to healthy volunteers, of the 96.94% total recovery, 96.62% of the administered radioactivity was recovered in feces almost exclusively as the unchanged drug and 0.32% was recovered in urine mostly as metabolites with 0.03% as the unchanged drug.Rifaximin accounted for 18% of radioactivity in plasma. This suggests that the absorbed rifaximin undergoes metabolism with minimal renal excretion of the unchanged drug
In vitro drug interactions studies have shown that rifaximin, at concentrations ranging from 2 to 200 ng/mL, did not inhibit human hepatic cytochrome P450 isoenzymes: 1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, and 3A4. In an in vitro hepa-tocyte induction model, rifaximin was shown to induce cytochrome P450 3A4 (CYP3A4), an isoenzyme which rifampin is known to induce.
Approximately 6 hours.
Rifaximin acts by inhibiting RNA synthesis in susceptible bacteria by binding to the beta-subunit of bacterial deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase enzyme. This binding blocks translocation, which stops transcription.
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Certificate Number : CEP 2012-146 - Rev 02
Status : Valid
Issue Date : 2024-06-10
Type : Chemical
Substance Number : 2362
Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.
Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.
Certificate Number : CEP 2022-368 - Rev 00
Status : Valid
Issue Date : 2024-09-02
Type : Chemical
Substance Number : 2362
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2024-415 - Rev 00
Status : Valid
Issue Date : 2025-07-11
Type : Chemical
Substance Number : 2362

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2020-435 - Rev 00
Status : Valid
Issue Date : 2024-02-12
Type : Chemical
Substance Number : 2362

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R1-CEP 2010-085 - Rev 01
Status : Valid
Issue Date : 2018-10-12
Type : Chemical
Substance Number : 2362

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2021-420 - Rev 00
Status : Valid
Issue Date : 2023-06-06
Type : Chemical
Substance Number : 2362

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2020-175 - Rev 00
Status : Valid
Issue Date : 2022-12-07
Type : Chemical and TSE
Substance Number : 2362

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2016-016 - Rev 01
Status : Valid
Issue Date : 2024-02-28
Type : Chemical
Substance Number : 2362

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2019-125 - Rev 04
Status : Valid
Issue Date : 2025-07-25
Type : Chemical
Substance Number : 2362

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2024-520 - Rev 00
Status : Valid
Issue Date : 2025-02-06
Type : Chemical
Substance Number : 2362

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Application : Emulsifying Agents
Excipient Details : HDK N20 Pharma is used as a pharmaceutical emulsifying agent in tablets, capsules, syrups, and solutions.
Dosage Form : Suspension
Grade : Oral, Topical
Application : Rheology Modifiers
Excipient Details : HPMC 60HD4000 is used as thickener and viscosity modifier in oral solid, liquid and topical dosage forms.
Dosage Form : Suspension
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Brand Name : Titanium dioxide PRETIOX ...
Application : Coloring Agents
Excipient Details : Titanium dioxide Pretiox AV01FG is used as a coloring and coating agent in oral solid dosage forms such as capsules, tablets, granules, and pellets.
Pharmacopoeia Ref : Fami-QS, Kosher, Halal, OHSAS ...
Technical Specs : Ti 59.95% and O 40.05%
Ingredient(s) : Titanium Dioxide
Dosage Form : Tablet
Grade : Oral
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Capsule
Grade : Not Available
Application : Fillers, Diluents & Binders
Excipient Details : Tablet film coating, binders , main material of plant capsules.
Pharmacopoeia Ref : USP/BP/EP/CP
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Tablet
Grade : Oral
Brand Name : Microcrystalline Cellulos...
Application : Fillers, Diluents & Binders
Excipient Details : Tablet and capsule diluent, Tablet disintegrant.
Pharmacopoeia Ref : USP/BP/EP/CP
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose Excipients
Dosage Form : Tablet
Grade : Not Available
Application : Emulsifying Agents
Excipient Details : Glidant; Emulsion Stabilizer; Anti-caking Agent.
Dosage Form : Tablet
Grade : Not Available
Brand Name : Sodium Starch Glycolate
Application : Disintegrants & Superdisintegrants
Excipient Details : It is used as Tablet disintegrants
Pharmacopoeia Ref : USP/BP/EP/CP
Technical Specs : Not Available
Ingredient(s) : Sodium Starch Glycolate
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Tablet
Grade : Not Available
Brand Name : Kollicoat Protect
Application : Coating Systems & Additives
Excipient Details : Flexible water soluble instant release coating polymer, especially used for moisture protection
Pharmacopoeia Ref : Excipient based on Kollicoat®...
Technical Specs : Not Available
Ingredient(s) : Polyvinyl Alcohol Graft Polyethylene Glycol Copolymer
Dosage Form : Tablet
Grade : Not Available
Application : Film Formers & Plasticizers
Excipient Details : Liquid plasticizer with high ADI, hydrophilic solvent & humectant in emulsions, skin penetration enhancer in topical formulaitons.
Pharmacopoeia Ref : Ph. Eur., JP, FCC, USP
Technical Specs : Not Available
Ingredient(s) : Propylene Glycol
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Dosage Form : Tablet
Grade : Oral
Category : Direct Compression, Fillers, Diluents & Binders, Granulation
Application : Direct Compression, Fillers, Diluents & Binders, Granulation
Excipient Details : AceCel is suitable for majority of the directly compressible actives, combines good flow and high compressibility.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose Excipients
Application : Direct Compression
Pharmacopoeia Ref : Conforms to USP-NF, Ph.Eur., J...
Technical Specs : Density- Tapped density- 440 g/l, Bulk density- 310 g/l; Particl...
Ingredient(s) : Microcrystalline Cellulose Excipients
Dosage Form : Tablet
Grade : Oral
Category : Direct Compression, Fillers, Diluents & Binders, Granulation
Application : Direct Compression, Fillers, Diluents & Binders, Granulation
Excipient Details : HiCel acts as a strong dry binder. It facilitates low tablet friability & promotes rapid tablet disintegration.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose Excipients
Grade : Not Available
Category : API Stability Enhancers, Coating Systems & Additives, Controlled & Modified Release, Direct Compression, Granulation, Rheology Modifiers, Vegetarian Capsules
Application : API Stability Enhancers, Coating Systems & Additives, Controlled & Modified Release, Direct Compression, Granulation, Rheology Modifiers, Vegetarian Capsules
Excipient Details : Controlled Release, Direct Compression,Wet Granulation,Tablet Coating, Liquid Solutions and Suspensions
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Tablet
Grade : Oral
Category : Co-Processed Excipients, Direct Compression, Fillers, Diluents & Binders, Lubricants & Glidants
Application : Co-Processed Excipients, Direct Compression, Fillers, Diluents & Binders, Lubricants & Glidants
Excipient Details : HiCel SMCC has unique combination which result in optimum compaction & superior flow properties.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose Excipients
Application : Direct Compression, Granulation
Excipient Details : HiCellac is used in direct compression & dry granulation suitable for low dose formulations where API content uniformity is critical.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Lactose Monohydrate
Brand Name : Microlex® MCC 101
Application : Direct Compression, Granulation
Excipient Details : Tablets made from these granules are typically easily disintegrated using conventional super disintegrates even when hard tablets are compressed.
Pharmacopoeia Ref : Monograph- USP/NF, JP/JPE
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose Excipients
Brand Name : Microlex® MCC 102
Application : Direct Compression
Pharmacopoeia Ref : Monograph- USP/NF, JP/JPE
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose Excipients
Dosage Form : Tablet
Grade : Oral
Category : Co-Processed Excipients, Direct Compression, Disintegrants & Superdisintegrants
Dosage Form : Tablet
Grade : Oral
Category : Direct Compression, Fillers, Diluents & Binders, Granulation
Application : Direct Compression, Fillers, Diluents & Binders, Granulation
Excipient Details : AceCel is suitable for majority of the directly compressible actives, combines good flow and high compressibility.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose Excipients
Dosage Form : Tablet
Grade : Oral
Category : Direct Compression, Fillers, Diluents & Binders, Granulation
Application : Direct Compression, Fillers, Diluents & Binders, Granulation
Excipient Details : HiCel acts as a strong dry binder. It facilitates low tablet friability & promotes rapid tablet disintegration.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose Excipients
Grade : Oral
Category : Disintegrants & Superdisintegrants, Granulation, Lubricants & Glidants
Application : Disintegrants & Superdisintegrants, Granulation, Lubricants & Glidants
Application : Fillers, Diluents & Binders, Granulation
Pharmacopoeia Ref : EP./USP.NF
Technical Specs : NA
Ingredient(s) : Microcrystalline Cellulose Excipients
Grade : Not Available
Category : API Stability Enhancers, Coating Systems & Additives, Controlled & Modified Release, Direct Compression, Granulation, Rheology Modifiers, Vegetarian Capsules
Application : API Stability Enhancers, Coating Systems & Additives, Controlled & Modified Release, Direct Compression, Granulation, Rheology Modifiers, Vegetarian Capsules
Excipient Details : Controlled Release, Direct Compression,Wet Granulation,Tablet Coating, Liquid Solutions and Suspensions
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Tablet
Grade : Oral
Category : Coating Systems & Additives, Fillers, Diluents & Binders, Granulation
Application : Direct Compression, Granulation
Excipient Details : HiCellac is used in direct compression & dry granulation suitable for low dose formulations where API content uniformity is critical.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Lactose Monohydrate
Brand Name : Microlex® MCC 101
Application : Direct Compression, Granulation
Excipient Details : Tablets made from these granules are typically easily disintegrated using conventional super disintegrates even when hard tablets are compressed.
Pharmacopoeia Ref : Monograph- USP/NF, JP/JPE
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose Excipients
Dosage Form : Cream / Lotion / Ointment, Gel, Injectable / Parenteral, Softgels
Grade : Parenteral, Oral, Topical
Category : Film Formers & Plasticizers, Parenteral, Thickeners and Stabilizers, Topical
Brand Name : Hydroxypropyl Methyl Cellulose
Application : Coating Systems & Additives
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Emulsion, Tablet
Grade : Oral, Ophthalmic
Category : Disintegrants & Superdisintegrants, Emulsifying Agents, Film Formers & Plasticizers, Thickeners and Stabilizers
Brand Name : Hydroxypropyl Methyl Cellulose
Application : Disintegrants & Superdisintegrants, Emulsifying Agents, Film Formers & Plasticizers, Thickeners and Stabilizers
Excipient Details : Hydroxypropyl Methyl Cellulose is used as a film-former, disintegrant, thickener, and emulsifier in tablets, emulsions, and ophthalmic formulations.
Dosage Form : Capsule, Cream / Lotion / Ointment
Grade : Topical and Oral
Category : Film Formers & Plasticizers, Topical
Application : Film Formers & Plasticizers, Topical
Excipients Web Link
Grade : Not Available
Category : Fillers, Diluents & Binders, Film Formers & Plasticizers
Application : Fillers, Diluents & Binders, Film Formers & Plasticizers
Excipient Details : Tablet film coating, binders , main material of plant capsules.
Pharmacopoeia Ref : USP/BP/EP/CP
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Grade : Not Available
Category : Coating Systems & Additives, Film Formers & Plasticizers
Dosage Form : Capsule, Emulsion, Softgel Capsule, Solution, Tablet, Topical Film
Grade : Not Available
Category : Film Formers & Plasticizers, Solubilizers, Topical
Application : Film Formers & Plasticizers, Solubilizers, Topical
Excipient Details : Liquid plasticizer with high ADI, hydrophilic solvent & humectant in emulsions, skin penetration enhancer in topical formulaitons.
Pharmacopoeia Ref : Ph. Eur., JP, FCC, USP
Technical Specs : Not Available
Ingredient(s) : Propylene Glycol
Grade : Oral
Category : Coating Systems & Additives, Film Formers & Plasticizers
Application : Coating Systems & Additives, Film Formers & Plasticizers
Excipient Details : Ready mix Film coating system for moisture sensitive APIs
Pharmacopoeia Ref : USP, EP, JP; Having US-DMF
Technical Specs : Moisture barrier film coating system
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Grade : Oral
Category : Coating Systems & Additives, Film Formers & Plasticizers
Application : Coating Systems & Additives, Film Formers & Plasticizers
Excipient Details : Ready mix Non-Functional film coating system.
Pharmacopoeia Ref : USP, EP, JP; Having US-DMF
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2027-09-02
US Patent Number : 8193196
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 21361
Patent Use Code : U-1707
Delist Requested :
Patent Use Description : TREATMENT OF IRRITABLE...
Patent Expiration Date : 2027-09-02

Patent Expiration Date : 2026-02-27
US Patent Number : 9271968
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 21361
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-02-27

Patent Expiration Date : 2029-02-26
US Patent Number : 11564912
Drug Substance Claim :
Drug Product Claim :
Application Number : 21361
Patent Use Code : U-3511
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-02-26

Patent Expiration Date : 2026-02-27
US Patent Number : 10703763
Drug Substance Claim :
Drug Product Claim :
Application Number : 21361
Patent Use Code : U-1708
Delist Requested :
Patent Use Description : TREATMENT OF IRRITABLE...
Patent Expiration Date : 2026-02-27

Patent Expiration Date : 2029-10-02
US Patent Number : 8969398
Drug Substance Claim :
Drug Product Claim :
Application Number : 21361
Patent Use Code : U-1481
Delist Requested :
Patent Use Description : REDUCTION IN RISK OF O...
Patent Expiration Date : 2029-10-02

Patent Expiration Date : 2027-09-02
US Patent Number : 8193196
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 21361
Patent Use Code : U-1708
Delist Requested :
Patent Use Description : TREATMENT OF IRRITABLE...
Patent Expiration Date : 2027-09-02

Patent Expiration Date : 2025-06-01
US Patent Number : 7906542
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 21361
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2025-06-01

Patent Expiration Date : 2029-02-26
US Patent Number : 11564912
Drug Substance Claim :
Drug Product Claim :
Application Number : 21361
Patent Use Code : U-3512
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-02-26

Patent Expiration Date : 2029-02-26
US Patent Number : 10765667
Drug Substance Claim :
Drug Product Claim :
Application Number : 21361
Patent Use Code : U-2644
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-02-26

Patent Expiration Date : 2029-07-24
US Patent Number : 8946252
Drug Substance Claim :
Drug Product Claim :
Application Number : 21361
Patent Use Code : U-1481
Delist Requested :
Patent Use Description : REDUCTION IN RISK OF O...
Patent Expiration Date : 2029-07-24

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Patent Expiration Date : 2024-11-04
Date Granted : 2011-04-19
Brand Name : ZAXINE
Patent Number : 2538546
Filing Date : 2004-11-04
Strength per Unit : 550 mg
Dosage Form : Tablet
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2024-11-04
Date Granted : 2011-04-19

Patent Expiration Date : 2026-02-27
Date Granted : 2010-09-14
Brand Name : ZAXINE
Patent Number : 2594789
Filing Date : 2006-02-27
Strength per Unit : 550 mg
Dosage Form : Tablet
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2026-02-27
Date Granted : 2010-09-14

Patent Expiration Date : 2029-10-02
Date Granted : 2019-08-27
Brand Name : ZAXINE
Patent Number : 2739436
Filing Date : 2009-10-02
Strength per Unit : 550 mg
Dosage Form : Tablet
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2029-10-02
Date Granted : 2019-08-27

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.
CAS Number : 14487-05-9
Quantity Per Vial :
Price ($) : 700
Catalog Number : 1A03810
Current Lot : 25 mg
Previous Lot :
NDC Code :
ABOUT THIS PAGE
82
PharmaCompass offers a list of Rifaximin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rifaximin manufacturer or Rifaximin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rifaximin manufacturer or Rifaximin supplier.
PharmaCompass also assists you with knowing the Rifaximin API Price utilized in the formulation of products. Rifaximin API Price is not always fixed or binding as the Rifaximin Price is obtained through a variety of data sources. The Rifaximin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Fatroximin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fatroximin, including repackagers and relabelers. The FDA regulates Fatroximin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fatroximin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Fatroximin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Fatroximin supplier is an individual or a company that provides Fatroximin active pharmaceutical ingredient (API) or Fatroximin finished formulations upon request. The Fatroximin suppliers may include Fatroximin API manufacturers, exporters, distributors and traders.
click here to find a list of Fatroximin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Fatroximin DMF (Drug Master File) is a document detailing the whole manufacturing process of Fatroximin active pharmaceutical ingredient (API) in detail. Different forms of Fatroximin DMFs exist exist since differing nations have different regulations, such as Fatroximin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Fatroximin DMF submitted to regulatory agencies in the US is known as a USDMF. Fatroximin USDMF includes data on Fatroximin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Fatroximin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Fatroximin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Fatroximin Drug Master File in Japan (Fatroximin JDMF) empowers Fatroximin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Fatroximin JDMF during the approval evaluation for pharmaceutical products. At the time of Fatroximin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Fatroximin suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Fatroximin Drug Master File in Korea (Fatroximin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Fatroximin. The MFDS reviews the Fatroximin KDMF as part of the drug registration process and uses the information provided in the Fatroximin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Fatroximin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Fatroximin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Fatroximin suppliers with KDMF on PharmaCompass.
A Fatroximin CEP of the European Pharmacopoeia monograph is often referred to as a Fatroximin Certificate of Suitability (COS). The purpose of a Fatroximin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Fatroximin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Fatroximin to their clients by showing that a Fatroximin CEP has been issued for it. The manufacturer submits a Fatroximin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Fatroximin CEP holder for the record. Additionally, the data presented in the Fatroximin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Fatroximin DMF.
A Fatroximin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Fatroximin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Fatroximin suppliers with CEP (COS) on PharmaCompass.
A Fatroximin written confirmation (Fatroximin WC) is an official document issued by a regulatory agency to a Fatroximin manufacturer, verifying that the manufacturing facility of a Fatroximin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Fatroximin APIs or Fatroximin finished pharmaceutical products to another nation, regulatory agencies frequently require a Fatroximin WC (written confirmation) as part of the regulatory process.
click here to find a list of Fatroximin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Fatroximin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Fatroximin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Fatroximin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Fatroximin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Fatroximin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Fatroximin suppliers with NDC on PharmaCompass.
Fatroximin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fatroximin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fatroximin GMP manufacturer or Fatroximin GMP API supplier for your needs.
A Fatroximin CoA (Certificate of Analysis) is a formal document that attests to Fatroximin's compliance with Fatroximin specifications and serves as a tool for batch-level quality control.
Fatroximin CoA mostly includes findings from lab analyses of a specific batch. For each Fatroximin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fatroximin may be tested according to a variety of international standards, such as European Pharmacopoeia (Fatroximin EP), Fatroximin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fatroximin USP).